Sara Tolaney
MD, MPH
Associate Director, Breast Oncology Program
👥Biography 个人简介
Sara Tolaney at Dana-Farber is a leading clinical investigator in breast cancer, particularly noted for her work on immunotherapy in triple-negative breast cancer. She has contributed to the development and clinical evaluation of atezolizumab and pembrolizumab in early and metastatic TNBC, including work related to IMpassion130. Her research encompasses novel combination strategies, ADC-immunotherapy combinations, and biomarker development for treatment selection in TNBC. She is a sought-after educator and frequently presents seminal TNBC trial results at major oncology meetings.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Sara Tolaney 的研究动态
Follow Sara Tolaney's research updates
留下邮箱，当我们发布与 Sara Tolaney（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment